Generics Lobby Floats Alternative To FDA Drug Labeling Plan

Law360, New York (January 30, 2014, 2:38 PM EST) -- The Generic Pharmaceutical Association on Wednesday denounced the U.S. Food and Drug Administration's plan to let generics makers independently change their warning labels, floating an alternative to a proposal it said would create an “exponentially increasing litigation risk” for its members.

In an 11-page white paper, the GPhA all but accused the FDA of abandoning its long-held opposition to such label updates in order to help trial lawyers whose state failure-to-warn lawsuits against generic-drug manufacturers were barred by the U.S. Supreme Court's 2011 decision in Pliva...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.